BLUE-OCEAN-ROBOTICS
15.6.2020 15:04:13 CEST | Business Wire | Press release
Blue Ocean Robotics announced it has been included in Robotics Business Review’s list of the 50 most influential robotics companies in the world (RBR50 ) for its UVD Robots . The recognition was earned for work with UVD Robot, the health benefits of its technology and the continued growing demand for its disinfecting capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005041/en/
UVD Robots combines deep microbiological know-how, autonomous robot technology and ultraviolet light to create the world’s best UV-C based disinfection solution, proven to eliminate pathogens within 10-15 minutes in a room. The robots have been rolled out to more than 60 countries worldwide.
“UVD Robots has more than 75% of the world market of autonomous mobile UV-C disinfection robots,” says Claus Risager, CEO at Blue Ocean Robotics. “With the anticipated future growth, our 2-4 year lead on competitors with patented solutions, we are the dominant player for the future.”
Founded through a collaboration with Odense University Hospital, Blue Ocean Robotics created UVD Robots as a subsidiary in 2014 to solve the problem of Hospital Acquired Infections (HAI). One in fifteen people get infected in hospitals.
Eugene Demaitre, senior editor at The Robot Report and Robotics Business Review, said, “The solution was introduced to the market even before the COVID-19 pandemic, and since then UVD Robots has been able to scale its production to the growing global demand for automated disinfection. We expect that the Danish RBR50 company will, in the future, help both hospitals and other localities prevent infections as well.”
About Blue Ocean Robotics
Blue Ocean Robotics
develops, produces and sells professional service robots in healthcare, hospitality, construction, agriculture, and other global markets. The portfolio of robots includes brands; UVD Robots
, a mobile robot for disinfection; GoBe Robots
, a mobile telepresence robot for communication, social inclusion, and CO2 climate improvements; and PTR Robots
, a mobile robot for safe patient handling and rehabilitation. Blue Ocean Robotics develops the robots from problem and idea all the way to scale up. Each robot is placed in its own subsidiary-venture company, making Blue Ocean Robotics the world’s first Robot Venture Factory.
Download the press kit here
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Only AI Crypto Lead Prioritization Solution Built With Law Enforcement, for Law Enforcement: Elliptic Launches Pulse24.9.2026 15:15:00 CEST | Press release
Pulse delivers actionable leads in seconds, no crypto expertise required, enabling decisions in the field Elliptic, the global leader in on-chain risk, today launched Pulse. Pulse puts crypto lead prioritization directly in the hands of every frontline law enforcement and government officer. Crypto now touches every part of law enforcement, from the patrol officer on the street to the detective assigned to investigate the case. Pulse gives each of them a quick, accurate financial summary and a starting point: whether that's a crypto address on a suspect's phone, in a scam ATM victim's receipt, uncovered during a vehicle or pocket search, or found at the scene of an overdose, an arrest, or a seizure. An officer can input anything that looks like a wallet address or transaction hash. Pulse identifies it, reasons over the result, and returns a summary in plain language, enough for the officer to decide on the spot whether the case needs escalation. If a case needs further investigation, o
Just 4.7% of Financial Institutions Continuously Update Their Compliance Monitoring and Controls as Risk Changes, New Research Finds24.9.2026 15:04:00 CEST | Press release
As financial crime threats, regulations and transaction volumes evolve dynamically, most compliance programs remain built around periodic review SymphonyAI, a global leader in vertical AI product platforms, and AML Intelligence, the leading source of news and insight for the financial crime compliance community, today released the FinCrime Frontier 2026–27 Report, finding that most financial institutions still rely on periodic review cycles to manage financial crime risk, even as the threats and regulations they are meant to track continue to evolve dynamically. Based on the perspectives of more than 200 financial crime and compliance leaders, including senior leaders from major global financial institutions, the research finds that just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, while 56.8% have not adopted always-on compliance monitoring at all, are only exploring it, or remain at an early, pilot-stage level. The findi
SymphonyAI Introduces Symphony Risk Intelligence, an Agent-native Platform That Unlocks Always-on Compliance™ — the Catalyst for Transforming the Financial Crime Operating Model24.9.2026 15:04:00 CEST | Press release
New industry research finds just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, a gap regulators are now pushing institutions to close SymphonyAI today introduced Symphony Risk Intelligence (SRI), an enterprise-grade, agent-native platform built to unlock Always-on Compliance™. This is a critical shift from periodic to continuous risk and compliance management, in which institutions continuously reassess risk and adapt controls as regulations, threats and business activity change, rather than waiting for the next scheduled review. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924914614/en/ Current approaches have reached their structural limits. The FinCrime Frontier 2026–27 Report, released recently by SymphonyAI and AML Intelligence, finds just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, and 76
Boomi Appoints Mike Hickman as Chief Financial Officer24.9.2026 15:00:00 CEST | Press release
Three-decade technology finance leader joins Boomi to scale global operations, bringing experience across IPO, take-private, and large-scale acquisition integration Boomi, the data activation company for AI, today announced the appointment of Mike Hickman as Chief Financial Officer. Hickman will lead Boomi's global finance and accounting organization, spanning financial planning and analysis, accounting, treasury, tax, and financial reporting. He reports to Boomi Chairman and Chief Executive Officer Steve Lucas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924761566/en/ Boomi Appoints Mike Hickman as Chief Financial Officer Hickman brings three decades of senior finance leadership in high-growth SaaS and technology companies, with experience across the full corporate lifecycle: scaling through IPO, executing a take-private, and integrating large acquisitions. He joins from Proofpoint, where he spent seven and a half yea
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom